By Fineline Cube 
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic biotech company Tong Eye to co-develop iPSC-derived retinal pigment epithelial (RPE) cell therapies for ophthalmic diseases. This collaboration aims to advance innovative treatments for conditions affecting the eyes.
Partnership Details
Under the agreement, Porton Pharma will provide comprehensive end-to-end CMC services. These include process development for GMP-compliant iPSC differentiation, analytical method validation, IND-enabling studies, and regulatory support for filings with both China’s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). The financial terms of the partnership have not been disclosed.-Fineline Info & Tech